Hoth Therapeutics (HOTH)
(Delayed Data from NSDQ)
$0.74 USD
-0.05 (-6.70%)
Updated Oct 10, 2024 03:27 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Income Statements
Fiscal Year end for Hoth Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 8 | 11 | 14 | 7 | 8 |
Income After Depreciation & Amortization | -8 | -11 | -14 | -7 | -8 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -8 | -11 | -14 | -7 | -8 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -8 | -11 | -14 | -7 | -8 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -8 | -11 | -14 | -7 | -8 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -8 | -11 | -14 | -7 | -8 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -8 | -11 | -14 | -7 | -8 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 3.41 | 1.20 | 0.89 | 0.50 | 0.37 |
Diluted EPS Before Non-Recurring Items | -2.30 | -9.50 | -16.00 | -14.50 | -21.00 |
Diluted Net EPS (GAAP) | -2.30 | -9.50 | -16.00 | -14.50 | -21.00 |
Fiscal Year end for Hoth Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 1.65 | 2.06 | 1.72 | 2.09 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -1.65 | -2.06 | -1.72 | -2.09 |
Non-Operating Income | NA | 0.01 | 0.01 | -0.01 | 0.01 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -1.63 | -2.04 | -1.70 | -2.09 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -1.63 | -2.04 | -1.70 | -2.09 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -1.63 | -2.04 | -1.70 | -2.09 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 6.88 | 4.40 | 3.41 | 3.48 |
Diluted EPS Before Non-Recurring Items | NA | -0.24 | -0.46 | -0.31 | -0.60 |
Diluted Net EPS (GAAP) | NA | -0.24 | -0.46 | -0.25 | -0.60 |